CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

@article{Rydstrm2010CD40IA,
  title={CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.},
  author={Karin Rydstr{\"o}m and Johan Linderoth and Heidi Nyman and Mats Ehinger and Patrick Joost and P{\"a}r-Ola Bendahl and Sirpa Lepp{\"a} and Mats Jerkeman},
  journal={Leukemia & lymphoma},
  year={2010},
  volume={51 9},
  pages={
          1643-8
        }
}
We have previously shown that expression of CD40 has a favorable prognostic impact in diffuse large B-cell lymphoma (DLBCL) after anthracycline-based chemotherapy. Here we examined the prognostic value of immunohistochemically defined CD40 expression in 95 patients with DLBCL treated with both anthracycline-based chemotherapy and rituximab. Using a 10% cut-off level, 77% of the patients had CD40-positive tumors and showed a superior overall survival (p = 0.02 log-rank, hazard ratio 0.35, 95% CI… CONTINUE READING
BETA

Similar Papers

Loading similar papers…